Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

One step forward, two steps back: The story of everolimus in advanced breast cancer.

Niraula S, Ocana A, Amir E.

Breast. 2015 Oct;24(5):529-31. doi: 10.1016/j.breast.2015.04.006. Epub 2015 Jun 23.

PMID:
26112664
2.

Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.

Divers J, O'Shaughnessy J.

Clin J Oncol Nurs. 2015 Aug;19(4):468-74. doi: 10.1188/15.CJON.468-474.

PMID:
26207713
3.

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

Pascual T, Apellániz-Ruiz M, Pernaut C, Cueto-Felgueroso C, Villalba P, Álvarez C, Manso L, Inglada-Pérez L, Robledo M, Rodríguez-Antona C, Ciruelos E.

PLoS One. 2017 Jul 20;12(7):e0180192. doi: 10.1371/journal.pone.0180192. eCollection 2017.

4.

Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.

Thiery-Vuillemin A, Theodore C, Jacobasch L, Schmitz J, Papandreou C, Guillot A, Emmanouilides C, Slimane K, Kelkouli N, Kim S, Nguyen Tan Hon T.

Clin Genitourin Cancer. 2015 Jun;13(3):231-8. doi: 10.1016/j.clgc.2014.09.005. Epub 2014 Nov 20.

PMID:
25456838
5.

Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.

Xie J, Hao Y, Zhou ZY, Qi CZ, De G, Glück S.

Clin Breast Cancer. 2015 Oct;15(5):e263-76. doi: 10.1016/j.clbc.2015.04.001. Epub 2015 Apr 23.

PMID:
26048087
6.

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.

Lancet Oncol. 2015 Jul;16(7):816-29. doi: 10.1016/S1470-2045(15)00051-0. Epub 2015 Jun 16.

PMID:
26092818
7.

Everolimus: a new hope for patients with breast cancer.

Sendur MA, Zengin N, Aksoy S, Altundag K.

Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Review.

PMID:
24050600
8.

Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial.

Niikura N, Ota Y, Hayashi N, Naito M, Kashiwabara K, Watanabe K, Yamashita T, Mukai H, Umeda M.

Jpn J Clin Oncol. 2016 Sep;46(9):879-82. doi: 10.1093/jjco/hyw077. Epub 2016 Jun 30.

PMID:
27365521
9.

VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.

Santos LV, Cruz MR, Lopes Gde L, Lima JP.

Breast Cancer Res Treat. 2015 Jun;151(3):481-9. doi: 10.1007/s10549-015-3410-7. Epub 2015 May 7. Review.

PMID:
25947646
10.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

PMID:
26342236
11.

Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship.

Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche ML, Tubiana-Mathieu N, Venat-Bouvet L, Marquet P, Woillard JB.

Pharmacol Res. 2017 Jul;121:138-144. doi: 10.1016/j.phrs.2017.04.029. Epub 2017 May 1.

PMID:
28473246
12.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
13.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
14.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

15.

Bevacizumab for advanced breast cancer.

Goldfarb SB, Traina TA, Dickler MN.

Womens Health (Lond). 2010 Jan;6(1):17-25. doi: 10.2217/whe.09.71. Review.

PMID:
20001867
16.

Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.

Barnett CM.

Pharmacotherapy. 2009 Dec;29(12):1482-90. doi: 10.1592/phco.29.12.1482.

PMID:
19947807
17.

Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.

Yardley DA.

Clin Breast Cancer. 2014 Oct;14(5):297-308. doi: 10.1016/j.clbc.2014.03.002. Epub 2014 Jun 4. Review.

PMID:
25065566
18.

Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.

Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J.

J Comp Eff Res. 2015 Aug;4(4):315-26. doi: 10.2217/cer.15.25.

PMID:
26274793
19.

Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.

Lewis L, Taylor M, Suriya Ertugyrovna Y, Kuanysh Shadybayevich N, Kaldygul Kabakovna S, Ramil Zufarovich A.

J Med Econ. 2015 Mar;18(3):189-99. doi: 10.3111/13696998.2014.969432. Epub 2014 Nov 24.

PMID:
25415641
20.

Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.

Keck S, Glencer AC, Rugo HS.

Future Oncol. 2012 Nov;8(11):1383-96. doi: 10.2217/fon.12.143.

PMID:
23148612

Supplemental Content

Support Center